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ABSTRACT 
 
Objective 
The World Health Organization recommends that countries implement population-wide 
cardiovascular disease (CVD) risk assessment and management programmes. The aim of 
this study was to conduct a systematic review to evaluate whether this recommendation is 
supported by cost-effectiveness evidence.  
 
Methods  
Published economic evaluations were identified via electronic medical and social science 
databases (including Medline, Web of Science, and the NHS Economic Evaluation 
Database) from inception to March 2016. Study quality was evaluated using a modified 
version of the Consolidated Health Economic Evaluation Reporting Standards.  
 
Results  
14 economic evaluations were included: five studies based on randomised controlled trials, 
seven studies based on observational studies and two studies using hypothetical modelling 
synthesizing secondary data. Trial based studies measured CVD risk factor changes over 1 
to 3 years, with modelled projections of longer term events. Programmes were either not, or 
only, cost-effective under non-verified assumptions such as sustained risk factor changes. 
Most observational and hypothetical studies suggested programmes were likely to be cost-
effective; however, study deigns are subject to bias and subsequent empirical evidence has 
contradicted key assumptions. No studies assessed impacts on inequalities. 
 
Conclusion 
Recommendations for population-wide risk assessment and management programmes lack 
a robust, real world, evidence basis. Given implementation is resource intensive there is a 
need for robust economic evaluation, ideally conducted alongside trials, to assess cost 
effectiveness. Further, the efficiency and equity impact of different delivery models should be 
investigated, and also the combination of targeted screening with whole population 
interventions recognising that there multiple approaches to prevention. 
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INTRODUCTION 
 
Cardiovascular disease (CVD), type 2 diabetes, and kidney disease are major causes of 
mortality worldwide1. These diseases share common modifiable risk factors that include 
smoking, raised blood pressure, obesity, and physical inactivity2. CVD alone accounted for 
17.5 million deaths in 2012, representing 31% of all global deaths3. The prevalence of these 
conditions is increasing globally due to aging population and an increasing prevalence of risk 
factors such as obesity, posing major challenges to achieve the 25x25 non-communicable 
disease targets set by the World Health Organization (WHO)4.  
 
Many CVD events are preventable through changes in behavioural risk factors such as 
smoking and diet and pharmacological interventions. Clinical guidelines in Europe and 
several other countries support population wide programmes to assess and manage 
cardiovascular risk in individuals without pre-existing disease5 6. These consist of two 
sequential elements: (i) risk assessment of the adult population using a risk tool to assess 
global risk score. Individuals are then categorized into low, medium or high risk; (ii) referral 
to appropriate life style and pharmaceutical intervention in an effort to modify relevant risk 
factors. Examples of national CVD risk assessment and management programme include 
the NHS Health Check programme in England7, Keep Well in Scotland8 and More heart and 
diabetes checks in New Zealand9. 
 
For primary and secondary prevention of CVD, the WHO recommends implementation of 
cardiovascular risk assessment programmes in low resource settings10 11. For example, the 
WHO Package of Essential Noncommunicable (PEN) Disease includes CVD risk 
assessment and management as an integral part of prevention strategies for 
noncommunicable disease management10. Despite the growing enthusiasm for 
implementing these population-wide programmes worldwide there is on-going debate 
regarding whether these are cost effective, concern that health inequalities may increase, 
and whether screening should be prioritised and implemented in routine practice, especially 
given there are multiple potential prevention approaches12-14. The aim of this study was to 
conduct a systematic review to assess the cost effectiveness of CVD risk assessment and 
management programmes, hereon termed screening programmes. 
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METHODS 
 
We followed the methods detailed in a peer-reviewed systematic review protocol that is 
registered with PROSPERO (registration CRD 42014009470).  
 
Search strategy, inclusion criteria, and study selection 
 
We identified studies that conducted an economic evaluation of CVD risk assessment and 
management programmes, which included measuring multifactorial risk (including blood 
pressure, BMI, and smoking status) and referral to appropriate lifestyle and pharmaceutical 
interventions6 15. 
 
We retrieved articles by searching through the following databases; Medline, EMBASE, Web 
of Science, Cochrane Database of Systematic Reviews, Centre for Reviews and 
Dissemination databases, DARE (Database of Abstracts of Reviews of Effects), NHS EED 
(NHS Economic Evaluation Database), and HTA database (Health Technology 
Assessments). We created a search strategy involving keywords and subject headings 
tailored to each databases. The key words were:  
▪ Identifying diseases: “vascular disease”, “cardiovascular disease”, “coronary heart 
disease”, “myocardial infarction”, “cardiovascular events”, “blood pressure”, “hypertension”, 
“hypercholesterolemia”, “diabetes”, “stroke”, “kidney disease”, and “chronic disease”. 
▪ Identifying economic evaluation: “economic evaluation”, “quality-adjusted life years”, “cost-
benefit”, “cost-effectiveness”, “cost-consequences”, and “cost-utility”. 
▪ Identifying interventions: “risk factor”, “health check”, “community”, “prevention”, 
“intervention program”, “general practice”, “primary care”, “health education”, “health 
promotion”, “lifestyle intervention”, “smoking cessation”, “diet”, “obesity”, and “weight”. 
 
Inclusion and Exclusion Criteria  
 
We included all types of economic evaluation studies including cost-effectiveness, cost-
utility, and cost-benefit analyses. Included studies had a variety of outcome measures 
including: risk factors, CVD outcomes, utility (economic measure of morbidity), life years, 
event-free time, disability adjusted life years (DALYs), quality adjusted life years (QALYs), 
and studies with a net monetary impact (where all outcomes are converted into monetary 
terms).  
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Our searches covered all published research up to the last search performed in March 2016. 
No restriction was made on the type of risk assessment programme, geographical location, 
and population groups. We only included original studies, and not comments, letters, and 
review articles. We only included studies published in English. Reference Lists of all the 
included articles were screened for additional citations.  
 
Data extraction, quality assessment, and analysis 
 
Two reviewers (YW and JTL) independently screened articles by title and subsequently by 
abstract to select articles for further review. Full texts of articles were then retrieved and 
reference lists were manually searched to check for additional articles. All disagreements 
were resolved by consensus or by reference to the third reviewer (CM). 
 
Data were extracted from selected studies into data sheets with the following information 
included: 1) Intervention and risk factors targeted. 2) Population and settings. 3) Outcome 
and costs variables included. 4) Results from economic evaluation.  
 
As there is no standard quality assessment tools for cost-effectiveness analysis, we 
employed a modified version of the Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS)16 to evaluate the reporting quality of the studies included (see web 
appendix 2). We used arbitrary cut-offs to categorise studies into high/moderate/low quality. 
Studies with more than two thirds of items scored as done were defined as high quality, 
studies between one and two thirds were scored as moderate quality, and studies with less 
than one third were defined as low quality.  
 
In reporting the results, we first grouped studies by study design and the main source of 
data, including: (i) studies based on trial evaluation evidence; (ii) studies based on 
observational evidence; and (iii) studies that were hypothetical modelling studies, where 
there was not an evaluation of an actual programme, but where multiple secondary data 
sources where used and synthesized to generate ‘what if’ analyses. Within each group 
studies were described in reverse chronological order. For (i) we also reported whether an 
economic evaluation was conducted alongside the trial itself, with separate reporting of 
‘within’ trial’ results and longer term modelling using the trial outcomes. Quality of studies 
were ranked using the modified CHEERS tool described above. Due to heterogeneity in the 
study design, population, and outcome measures reported, no meta-analysis was 
conducted, instead we provided a critical assessment of each study.  
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RESULTS 
 
Figure 1 summarises search results in a PRISMA flowchart. In total, 9207 articles were 
identified through the search process and screened based on the title and abstract, and of 
these, 123 full-text articles were assessed for eligibility. 14 primary articles met the eligibility 
criteria were included in the final review. 
 
-Figure 1- 
 
Characteristics of the selected studies 
 
14 economic evaluations met the inclusion and exclusion criteria and were included in the 
review. Of these, five studies were based on randomised controlled trial evidence17-21, seven 
studies were based on observations evidence22-27, and two were based on hypothetical 
modelling28 29.  
 
In terms of the population studied, 10 economic evaluations originated from Europe17-21 27-29, 
two from Israel25 26, and two from the United States23 24. None of the studies were conducted 
in low and middle income settings. Most studies were categorised as middle or low quality 
except six recent studies which were graded as high quality (web appendix table 2).  
 
Most trials had a follow up less than 3 years and none had CVD events as their primary 
outcome measure. Modelling was used to project longer term events and costs using trial 
findings of changes in risk factors. The most commonly used economic measures were 
incremental costs per life-years gained (LYG) and incremental costs per quality-adjusted life 
year (QALY) gained. A detailed description of the studies is presented in table 1 and web 
appendix table 3. 
 
-Table 1- 
 
Intervention and risk factors targeted 
 
Although all interventions involved a general health check focused on modifiable 
cardiovascular risk factors, there was substantial variation in the individual risk factors 
assessed (see web appendix table 3). Risk factors most commonly assessed were blood 
pressure, body mass index (BMI), smoking status and cholesterol. Many interventions 
assessed additional risk factors including blood glucose, family history of CVD, alcohol 
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consumption, diet and physical activity. There was also substantial variation how individuals 
were prioritized for treatment and which interventions were offered. In general, most 
interventions include advice, such as diet and physical activity, and pharmaceuticals.  
 
Cost-effectiveness 
Findings from trial based studies 
EUROACTION20 was a matched, paired cluster randomised controlled trial of a nurse-lead 
CVD risk assessment and management programme in six European countries (Denmark, 
Italy, Netherlands, Poland, Spain and UK) conducted during 2003-2004. The programme 
include a CVD risk assessment followed by pharmaceutical and behavioural as appropriate.  
The trial measured individual risk factors such as blood pressure, BMI, cholesterol and 
glucose level etc., and has follow-up period of one year. Mistry et al (2012) undertook an 
economic evaluation and modelled possible effect on CVD events for the next 10 years, 
assuming intervention effect persist for 0 through to 10 additional years (11-year time 
horizon), after which they reverted to their individual CVD risk factor levels at the start of the 
study (adjusted for age). Their results suggested, after adjusting for individuals’ baseline 
characteristics, the intervention was dominated by the usual care in each year of projections 
(i.e. the intervention arm has higher costs but lower QALYs) and is unlikely to be cost-
effective. A separate analysis of the Polish component of the EUROACTION program 
suggests that the intervention may have been cost-effective in that setting19. However, the 
results are sensitive to model assumptions such as duration of the intervention effects which 
needed to last at least ten years for the intervention to be cost-effective. 
 
Oxcheck and the British Family Heart studies (BFHS)17 18 30 were randomised controlled trials 
based in UK conducted in the 1990s. The two studies recruited middle aged men and 
women (aged 35-64 in Oxcheck, and 40-59 in BFHS). Oxcheck and BFHS included nurse-
led CVD risk assessment followed by appropriate lifestyle advice and drug intervention in 
general practice. The follow-up period for these two trials were one (BFHS) and three 
(Oxcheck) years of respectively, with modest changes in risk factors. Wonderling et al 
(1996a,b) investigated the effectiveness and cost-effectiveness of these two interventions 
using life-years gain (LYG) as the main outcome measures. Their results suggested the 
overall reduction in coronary risk was estimated to be around 13% to 20% in the Oxcheck 
study and 12% in the British Family Heart Study, and the Oxcheck programme was only 
cost-effective if the intervention effect lasted at least five years, and it was 10 years in BFHS.  
 
Using information from the participants of the Oxcheck trial, Field (1995)21 compared the 
cost-effectiveness of six CVD risk factors screening strategies; 1) Blood pressure and 
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medical history, 2) + smoking, 3) + height and weight, 4) + diet, 5) + family history, 6) + 
blood cholesterol. This study found the most basic screening strategy was most cost-
effective, with increasing incremental costs per life year gained as the strategies become 
more comprehensive. Also, their results suggested the interventions were more cost 
effective if it targeted to high risk groups such as older men.  
 
Findings from observational studies 
The KardioPro is a risk assessment and management programme in Germany which 
targeted persons aged 45 years and above, as well as individuals with coronary heart 
disease (CHD). Patients with high risk were prescribed medication and risk factors were 
managed according to European guidelines. Aljutaili et al (2014) assessed the cost-
effectiveness of the intervention using maximum of four years follow-up data. Instead of 
using QALY or LYG as outcome measures, the primary outcome measured in this study was 
event-free days for death (all causes), myocardial infarction (MI) and stroke. The results of 
the study suggested the intervention was associated with gain of event-free days and it was 
highest in high CHD risk groups and lowest in low CHD risk group. In the cost-effectiveness 
analysis, their results reveal a wide range of cost-effectiveness ratios, ranging from €20,901 
(high CHD risk) to €186,074 (low CHD risk) per event-free year. Overall they conclude the 
intervention would be more cost-effective if it were targeted in high risk groups, including 
those with existing CHD.  
 
The Ashkelon Hypertension Detection and Control Program (AHDC) and Israeli Blood 
Pressure Control program (IBPC) were risk assessment programmes in Israel. Yosefy et al 
(2003 a, b) evaluated the cost-effectiveness of the intervention using reduction in CVD 
events as the primary outcome measures. Their study found both interventions were cost 
saving (i.e highly cost-effective) as the cost-offset due to improved health far outweighed the 
cost of the intervention. It is worth noting that the study applied a simple before and after 
comparison study design when assessing the effectiveness of the programme, therefore, the 
effectiveness of the intervention could be biased.  
 
The WISEWOMAN programme was a risk assessment intervention targeted at low income, 
underinsured and uninsured women aged 40-64 years in the US. The intervention included 
CVD risk assessment followed by appropriate lifestyle advice to develop a healthier diet, 
increase physical activity, and quit tobacco use. Finkelstein et al (2006) evaluated the cost-
effectiveness of the intervention using one year follow-up data of changes in risk factors and 
modelled through 10 year probability of developing coronary heart disease (CHD). Their 
results yield a large variation in cost-effectiveness ratio under different assumptions. For 
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example, the cost-effectiveness ratio was $4400 per discounted life-year gained under the 
best case scenario (the intervention effect sustained life-long), but the figure increased to 
$133,500 in the worse scenarios (the intervention effect only sustained for one year, and 
other assumptions on the missing data).  
 
Finkelstein et al (2002) further compared the cost-effectiveness of the WISEWOMAN 
programme with different intensity of follow up treatment: the minimum intervention (MI) and 
the enhanced intervention (EI). The minimum intervention included risk factor assessment 
and a one-on-one counselling session. The enhanced intervention included all the activities 
in the minimum intervention and other interventions such as further counselling sessions and 
group intervention activities to improve physical activity levels and nutrition. The study 
results did not suggest EI is more effective and cost-effective than MI.  
 
The Norsjo risk assessment programme was implemented in Sweden during 1985-1990. 
The intervention invited men and women aged 30-60 years for risk assessment followed by 
appropriate advice. Without a control group, Lindholm et al (1996) evaluated the 
effectiveness of the intervention by comparing changes in risk factors for the study 
population with those residing in neighbouring region over the study period. Their results 
suggested the intervention was highly cost-effective or even cost-saving. However, the 
observational data are prone to bias, the studies included lacked a control groups, and so in 
the absence of individual patient data it is difficult to confidently attribute changes in CVD 
risk and event to the programme itself, rather than general secular changes.   
 
Findings from economic modelling studies 
Schuetz et al (2013) simulated the likely cost-effectiveness if an NHS Health Check 
programme was implemented across 6 European countries: Denmark, France, Germany, 
Italy, Poland and UK. A hypothetical cohort of individuals aged 40-74 years were offered 
screening every 5 years. The model assumed population characteristics derived from US 
data, and also simulated health services in each country. The cost of screening was not 
included in the modelling. Individuals were screened and prioritized for treatment on the 
basis of inflated single risk factors, rather than using a global risk score. Cost per QALY was 
estimated over a 30 year time horizon. Results suggest that the screening programme would 
likely be cost effective with a cost per QALY ranging from 14,903 to cost saving. Sensitivity 
and scenario analysis untaken, where it was found that pre-screening strategies that 
targeted known high groups, such as the obese were more cost effective.  
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The NHS Health Check in England began in 2009 and invites 40-74 year olds to a general 
practitioner every 5 years to be screened using the QRISK2 global risk equation, with 
additional screening conditional upon patient history. GPs are advised to follow clinical 
guidelines to prioritise and treat patients using pharmaceutical and behavioural intervention, 
as appropriate. The UK Department of Health27 simulated potential cost-effectiveness of the 
programme by assuming risk factors distributions in the population, and varying assumptions 
regarding costs, uptake, compliance, attribution (no formal control group was included), 
costs, and sustainability of treatment (citing secondary studies). Cost per QALY was 
estimated over the lifetime of individuals. Results suggest that the screening programme 
would likely be highly cost-effective, with a mean cost per QALY of £2,480 (£2,417 - £2,617) 
Sensitivity and scenario analysis was undertaken with the programme still likely to be cost 
effective.   
 
DISCUSSION 
 
Summary and interpretation of findings 
The WHO and several national clinical guidelines recommend population wide CVD risk 
assessment and management programmes, consisting of estimating global CVD risk and 
onward referral to appropriate pharmaceutical and lifestyle interventions10 31. However, there 
is a lack of robust, real-world, economic evidence regarding the cost effectiveness and 
inequality impact of population-wide screening programmes.  
 
We found 14 studies assessing the cost-effectiveness of the intervention, of which five 
studies based on randomised controlled trials, seven studies based on observational studies 
and two studies using hypothetical modelling simulate “what-if” scenarios. No meta-analysis 
could be conducted given the heterogeneity between studies, such as variation in 
populations, screening approaches and interventions offered.   
 
Of the three randomised control trials included in this review, a single study conducted an 
economic evaluation alongside a clinical trial to ensure appropriate outcomes and costs 
were collected20. The screening programme was not cost-effective, either over the one year 
duration of the trial, or from modelled projections over 10 years to allow for CVD events to 
emerge. Other economic studies (over 20 years old) were based upon RCTs that measured 
risk factor changes, with modelled projections providing tentative evidence that programmes 
may be cost-effective if trial results continued without change for at least ten years. In 
contrast to RCTs, most observational studies suggested that screening programmes are 
cost-effective. However, many observational studies employed simple pre-post study 
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designs, without a control group, and the descriptions of the modelling approaches often 
lacked detail. Findings from both hypothetical modelling studies found that screening is likely 
to be highly cost-effective. However, these hypothetical studies are solely based on collating 
multiple secondary data sources and/or rely on key assumptions regarding model 
parameters, such as costs, uptake, compliance, attribution (given no control groups). Recent 
systematic reviews have cast doubt on applying key assumptions, and emerging evidence 
from England’s NHS Health Checks programme have contradicted key assumptions32 33, 
where uptake of the programme was found to be 21% in contrast to the 75% assumed in the 
modelling projections7. Further, doubts remain regarding the predictive accuracy in the 
epidemiological modelling from risk factors to clinical events34. 
 
All of the included studies were undertaken in high income settings such as Europe and US. 
There is a lack of evidence from low and middle income settings where 80% of the global 
non-communicable disease (NCD) mortality occur3. No studies assessed impacts on health 
inequalities in the population. 
 
Research recommendations  
Given the absence of robust evidence regarding cost effectiveness of screening 
programmes and the impacts on health inequalities, it seems prudent to recommend that 
economic evaluation should be conducted. For example, the overall cost of the UK’s Health 
Checks programme is estimated to be £243 million each year and intended to run in 
perpetuity28. Conducting evaluation is not a costless exercise and so there may be merit in 
formalizing the (economic) value of information from further research to reduce uncertainty 
regarding cost effectiveness. The need for robust evidence is perhaps especially important 
for low and middle countries faced with multiple challenges and yet have fewest resources to 
implement programmes31. Ideally evaluation should be alongside clinical trials to ensure 
appropriate outcomes and costs are collected, and with sufficient follow-up to provide 
confidence in key assumptions such as uptake and compliance behaviour. Recent studies 
have highlighted the importance of finding innovative ways to deliver CVD risk screening at 
lower cost in resources poor settings38 39.   
 
Economic modelling will remain important in future research to project results beyond trial 
duration to estimate events, costs and cost effectiveness. Nonetheless, modelling 
approaches can be improved and follow international modelling guidance35. This includes, 
for instance, validating the modelling process, assumptions used and predictions made 
where possible. Transparency in reporting modelling approaches would also help 
comparability of findings across settings and improve the confidence in results produced. 
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Further, while screening programmes are focussed on CVD, the interventions target risk 
factors (such as smoking and cholesterol) that are generic to a range of diseases (such as 
cancers and respiratory diseases), and so trials and modelling can usefully account for non-
CVD events. A related issue is that no economic models have assessed the full impacts on 
extending life expectancy on quality of life and health service costs from the expected 
increase in comorbidities.  
 
Future studies can usefully test not only the impact of population-wide screening but also 
explore the efficiency and equity impact of different screening approaches. Research has 
suggested that rather than screen the whole population from 40-74 years it may be more 
cost effective to include a pre-screening element given that high risk individuals are 
concentrated in known and identifiable groups such individuals who are older, have a family 
history, and living within deprived areas36 37. Further, economic analysis can usefully explore 
whether the cost effectiveness results of the programme (screening plus multiple 
interventions) is actually driven by specific elements and perhaps not everything included in 
the programme is cost effective. Only one study included in this review (Finkelstein et al 
2012) evaluated the cost-effectiveness of risk assessment programme with different follow-
up interview. For instance, it may be that smoking interventions, known to be highly cost 
effective, are driving the results and programmes could be made more efficient. Finally, an 
important issue is regarding implementation and whether the primary care system can 
absorb extra work load, or whether there is scope to drop and replace existing activities. 
Recent studies have highlighted the importance of finding innovative ways to deliver CVD 
risk screening at lower cost in resources poor settings38 39.   
 
Policy Implications  
With many countries having begun or considering implementing CVD risk assessment 
programmes, it is important that these interventions are properly tested to assess whether 
they are a cost effective use of resources, and to assess impacts on health inequalities. 
Policy should be aware of the possibility of improving the efficiency of screening approaches 
and delivery mechanisms, and also that that may be more optimal to combine targeted 
screening on known high risk groups with population approaches such as fiscal policies and 
legislative changes40. This may be especially important for low and middle-income countries 
where the bulk of the global CVD burden lies, and where health care resources are fewest. 
Overall, the primary prevention of CVD is likely to remain a high policy priority globally, and 
evidence based policymaking necessitates that the approach should be based on robust 
evidence of effectiveness, cost effectiveness and impacts on health inequalities.  
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Conclusion 
Recommendations for population-wide risk assessment and management programmes lack 
a robust, real world, evidence basis. Given implementation is resource intensive there is a 
need for robust economic evaluation, ideally conducted alongside trials, to assess cost 
effectiveness. Further, the efficiency and equity impact of different delivery models should be 
investigated, and also the combination of targeted screening with whole population 
interventions recognising that there multiple approaches to prevention. 
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FIGURES and TABLES 
Figure 1- Flow diagram of study design 
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Table 1- Results for Included Studies 
Study 
Design 
Reference Intervention and risk factors targeted Population and settings  Outcome and costs variables  Cost-effectiveness results  
RCT 
(Economic 
evaluation 
alongside 
RCT) 
Sovic et al 
(2013) 
EUROACTION 
component in 
Poland19 
This study is the Polish component of the 
EUROACTION project. The description of 
the EUROACTION project can be found in 
Mistry et al (2012) of this table. 
A total of 233 men and women from the 
intervention arm (average age of 56.5), and 
28 individuals from the control arm (average 
age of 57).  
Outcome measures: Quality adjusted life 
years (QALY). One year follow up period  
Incremental cost-effectiveness ratio (ICER) 
was 19,524 Poland Zloty for men and 82,262 
PLN for women. However, the results are 
sensitive to model assumptions such as 
changes of health states utilities and duration 
of the intervention effects. 
Costs variable: 
(1) Costs of screening and tests 
(2) Cost of drugs prescribed 
(3) Cost of other health service use including 
secondary care and medication 
RCT 
(Economic 
evaluation 
alongside 
RCT) 
Mistry et al 
(2012) 
EUROACTION 
Nurse-led risk assessments programme 
measuring CVD risk factors. Each patient was 
given a personal record card to record 
lifestyle and risk factor goals, medications 
and appointments.  
EUROACTION study was conducted 
between 2003-2006 in six European 
countries.  In total, 1019 patients in the 
intervention group, and 1005 in the control 
group. 
Outcome measures: Quality adjusted life 
years (QALYS). One year follow up period 
The intervention group is dominated by the 
usual care group (i.e higher costs but lower 
QALYs) in the fully adjusted model. 
Costs variable: 
(1) Costs of screening and tests 
(2) Cost of drugs prescribed 
(3) Cost of other health service use including 
secondary care and medication 
RCT 
Wonderling et 
al. (1996a) The 
British Family 
Heart Study 
Risk assessment involved multiple risk 
factors. Risk stratified determined follow-up 
from either every two months (the highest 
risk group) to once a year (the lowest risk 
group).    
13 general practices across UK in the 1990s. 
Intervention group: 1767 men aged 40-59 and 
1217 women. Control group: 2174 men and 
1402 women. 
Outcome measures: Coronary risk reduction. 
One year follow up period. 
The cost effectiveness was estimated at £4.3 
per 1 percentage reduction in coronary risk.  
Costs variable: 
(1) Cost of  screening and tests 
(2) Cost of drugs prescribed 
(3) Cost of other health service use 
RCT 
Wonderling 
(1996b) 
Oxcheck and 
British Family 
Heart Studies 
Oxcheck and British Family Heart Study 
Population in Oxcheck and British Family 
Heart Study 
Outcome measures: Life-years gain (LYG) 
Cost per life year gain ranged from £34800  
to £1500 for British family heart study, and 
from £29300 to £900 for Oxcheck. 
Costs variable:  
Same as Oxcheck and BFHS 
RCT 
Field et al 
(1995) 
This study simulated costs and cost-
effectiveness of 6 CVD risk factors screening 
strategies; 1) Blood pressure and medical 
history, 2) + smoking, 3) + height and weight, 
4) + diet, 5) + family history, 6) + blood 
cholesterol.    
A modelling study based on population 
attended OXCHECK trial in Bedfordshire in 
1993. The population studied was 7840 men 
and women aged 35-64. 
Outcome measures: Life-years gain (LYG) 
The most basic screening strategy was most 
cost effective, with increasing cost per life 
year gain as the strategies become more 
comprehensive. Interventions are more cost 
effective in men than women, and in older 
rather than younger population. 
Costs variable:  
(1) Cost of screening and tests 
(2) Cost of drugs prescribed  
(3) Cost of conducting intervention session 
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Table 1 continued- Results for Included Studies 
 Study 
Design 
Reference Intervention and risk factors targeted Population and settings Outcome and costs variables  Cost-effectiveness results  
Observational 
Study 
Aljutaili et al 
(2014) 
KardioPro 
Risk assessment involved multiple risk 
factors. Risk stratified followed by a tailored 
lifestyle intervention and medical 
interventions. 
Insured people aged 45 years and above, as 
well as subjects with coronary heart disease. 
All subjected were enrolled in KardioPro 
intervention from 2007-2009 (13,116 
individuals).  
Outcome measures: 1) event free time for all-
cause mortality, acute myocardial infarction 
and ischemic stroke  Estimates for cost per event-free year ranges 
from €20,901 (high CHD risk population) to 
€186,074 (low CHD risk population). 
Cost included: 
(1) Costs of screening and tests 
(2) Medical costs associated with CVD events 
Observational 
Study 
Finkelstein et al 
(2006) 
WISEWOMEN 
WISEWOMAN project provided risk 
assessment, and followed by a tailored 
lifestyle intervention. 
The programmes targeted low income, 
underinsured and uninsured women aged 40-
64. This study used data from nine projects 
across US from 2000-2003, with a total of 
3015 women participants.  
Outcome measures: 10 year risk of coronary 
heart disease; Life-years gained (LYG). One 
year follow up period. $470 to achieve an average of 1 percentage 
point reduction in CHD risk, which translates 
into a cost-effectiveness ratio of $4400 per 
life year gain. 
Costs variable: 
(1) Cost of screening and tests 
(2) Cost of conducting intervention sessions 
(3) Cost of providing outreach 
Observational 
Study 
Finkelstein et al 
(2002) 
WISEWOMAN 
Two levels of WISEWOMAN CVD 
screening programme. The minimum 
intervention included a risk factors screening 
and one-on-one counselling session. The 
enhanced intervention, which included all 
these activities mentioned above and other 
intervention activities such as further 
counselling sessions and group intervention 
activities etc.   
Low income, underinsured and uninsured 
women in Massachusetts, US. 819 women 
were recruited into the intervention group, 
and 767 in the comparison group. 
Outcome measures: 10 year risk of coronary 
heart disease. One year follow up period. There was a larger but not statistically 
significant reduction in 10 year CHD risk for 
those received intensive treatment compared 
to normal treatment. The results suggested 
$637 to achieve a 1 percentage point decrease 
in the 10 year probability of CHD, $5000 for 
one life-year gained.  
Costs variable: 
(1) Cost of screening and tests 
(2) Cost of conducting intervention sessions 
(3) Cost of providing outreach  
Observational 
Study 
Yosefy et al 
(2003a) AHDC 
Program 
CVD risks screening, and high risk patients 
underwent an intensive CVD risk factor 
control program.   
Ashkelon in Israel. During 1980-1990, the 
program examined 12002 subjects (6833 Men 
and 5369 Women) aged 20- 65.  
Outcome measures: 1) Standardized mortality 
ratio 2) Life year gain After taking into account the cost saving due 
to improved health, the cost of the programme 
was offset by cost saving due to improved 
health. 
Costs variable: 
(1) Overall programme costs 
(2) Cost of other health service use  
Observational 
Study 
Yosefy et al 
(2003b) IBPC 
program 
Physicians recorded patients' risk factors and 
medications for all patients with hypertension. 
4948 patients with hypertension (mean age of 
64.6) from 30 general practice clinics across 
Israel. The Israeli Blood Pressure Control 
(IBPC) program was initiated in the year 
2000.  
Outcome measures: Acute myocardial 
infarctions event 
The cost of the intervention was offset by cost 
saving due to improved health, gives a net 
saving of $977,993. 
Costs variable: 
(1) Costs of screening and tests 
(2) Cost of drugs prescribed 
(3) Cost of other health service use including 
secondary care and medication 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
 
 
21 
 
 
Table 1 continued- Results for Included Studies  
 
Study Design Reference Intervention and risk factors targeted Population and settings  Outcome and costs variables  Cost-effectiveness results  
Observational 
Study 
Langham et 
al. (1996) 
The Oxcheck 
Study 
Nurses performed checks with defined 
protocol. Risk score used to stratify patients, 
high risk patients returned for follow-up.  
Five general practices in Luton and Dunstable 
in England during 1989-1993. Intervention 
group: 2205 Men and Women aged 35-64. 
Control group: comparable group of 1916 
individuals.   
Outcome measures: reduction in the relative 
risk of cardiovascular disease. Three years 
follow up period. 
The overall reduction in coronary risk was 
between 13% to 20%. Cost per 1% reduction 
in coronary risk was between £1.46 and £2.25.  
Costs variable: 
(1) Costs of screening and tests 
(2) Cost of drugs prescribed 
(3) Cost of other health service use 
Observational 
Study 
Lindholm et 
al (1996)  
Nurses performed screening annually which 
comprising of medical exam, lifestyle 
questionnaire, advice on main risk factors for 
cardiovascular disease.  
 Norsjo, Sweden during 1985-1990. 5500 
(men and women aged 30-60 years) were 
invited for risk factor screening, and overall 
1498 individual were screened. Control group 
were those live in other countries in Sweden. 
Outcome measures: Life-years gain (LYG) 
From societal perspective, cost per life year 
gain ranged from £14900 to net saving. 
Costs variable: 
(1) Cost of screening and tests 
(2) Cost of other health service use including 
secondary care  
(3) Societal cost  
Economic 
Modelling 
Schuetz et al 
(2013)  
Risk assessment involved multiple risk 
factors. Risk stratified followed by a tailored 
lifestyle intervention and medical 
interventions. 
Population aged 40–74 years in 6 European 
countries: Denmark, France, Germany, Italy, 
Poland and UK  
Outcome measures: 1) Major adverse 
cardiovascular events 2) Quality adjusted life 
years (QALY).  
This study found the interventions are likely to 
be cost-effective in most countries with cost 
per QALY ranging from cost-saving in Poland 
to €14903 in France. The intervention would 
be more cost-effective if targeted on higher 
risk groups such as the elderly or overweight 
population. 
Costs variable: 
(1) Cost of screening and tests 
(2) Costs of providing interventions 
(3) Costs associated with vascular disease  
Economic 
Modelling 
Department 
of Health, 
UK 
Risk assessment involved multiple risk 
factors. Risk stratified followed by a tailored 
lifestyle intervention and medical 
interventions. 
Population aged 40–74 years in England, who 
are not currently on a vascular disease register.  
Outcome measures: Quality adjusted life years 
(QALYS). 
the intervention is highly cost-effective, with 
an estimate of its cost per QALY of around 
£3,000 
Costs variable: 
(1) Cost of screening and tests 
(2) Life time cost after receiving interventions 
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Web Appendix 
Appendix Table 1- Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) 
Section/item Recommendation 
Title and abstract   
1. Title 
Identify the study as an economic evaluation or use more specific terms such as “cost-
effectiveness analysis”, and describe the interventions compared. 
2. Abstract 
Provide a structured summary of objectives, perspective, setting, methods (including study 
design and inputs), results (including base case and uncertainty analyses), and 
conclusions. 
Introduction 
3. Background and objectives Provide an explicit statement of the broader context for the study. 
Methods 
4. Target population and subgroups 
Describe characteristics of the base case population and subgroups analysed, including 
why they were chosen. 
5. Setting and location State relevant aspects of the system(s) in which the decision(s) need(s) to be made. 
6. Study perspective Describe the perspective of the study and relate this to the costs being evaluated. 
7. Comparators Describe the interventions or strategies being compared and state why they were chosen. 
8. Time horizon 
State the time horizon(s) over which costs and consequences are being evaluated and say 
why appropriate. 
9. Discount rate 
Report the choice of discount rate(s) used for costs and outcomes and say why 
appropriate. 
10. Choice of health outcomes 
Describe what outcomes were used as the measure(s) of benefit in the evaluation and their 
relevance for the type of analysis performed. 
11. Measurement of effectiveness 
Single study-based estimates: Describe fully the design features of the single effectiveness 
study and why the single study was a sufficient source of clinical effectiveness data. 
  
Synthesis-based estimates: Describe fully the methods used for identification of included 
studies and synthesis of clinical effectiveness data. 
12. Measurement and valuation of preference 
based outcomes 
If applicable, describe the population and methods used to elicit preferences for outcomes. 
13. Estimating resources and costs 
Single study-based economic evaluation: Describe approaches used to estimate resource 
use associated with the alternative interventions. Describe primary or secondary research 
methods for valuing each resource item in terms of its unit cost. Describe any adjustments 
made to approximate to opportunity costs. 
  
Model-based economic evaluation: Describe approaches and data sources used to 
estimate resource use associated with model health states. Describe primary or secondary 
research methods for valuing each resource item in terms of its unit cost. Describe any 
adjustments made to approximate to opportunity costs. 
14. Currency, price date, and conversion 
Report the dates of the estimated resource quantities and unit costs. Describe methods for 
adjusting estimated unit costs to the year of reported costs if necessary. Describe methods 
for converting costs into a common currency base and the exchange rate. 
15. Choice of model 
Describe and give reasons for the specific type of decision-analytical model used. 
Providing a figure to show model structure is strongly recommended. 
16. Assumptions Describe all structural or other assumptions underpinning the decision-analytical model. 
17. Analytical methods 
Describe all analytical methods supporting the evaluation. This could include methods for 
dealing with skewed, missing, or censored data; extrapolation methods; methods for 
pooling data; approaches to validate or make adjustments (such as half cycle corrections) 
to a model; and methods for handling population heterogeneity and uncertainty. 
Results 
18. Study parameters 
Report the values, ranges, references, and, if used, probability distributions for all 
parameters. Report reasons or sources for distributions used to represent uncertainty 
where appropriate. Providing a table to show the input values is strongly recommended. 
19. Incremental costs and outcomes 
For each intervention, report mean values for the main categories of estimated costs and 
outcomes of interest, as well as mean differences between the comparator groups. If 
applicable, report incremental cost-effectiveness ratios. 
20. Characterising uncertainty 
Single study-based economic evaluation: Describe the effects of sampling uncertainty for 
the estimated incremental cost and incremental effectiveness parameters, together with 
the impact of methodological assumptions (such as discount rate, study perspective). 
  
Model-based economic evaluation: Describe the effects on the results of uncertainty for all 
input parameters, and uncertainty related to the structure of the model and assumptions. 
21. Characterising heterogeneity 
If applicable, report differences in costs, outcomes, or cost-effectiveness that can be 
explained by variations between subgroups of patients with different baseline 
characteristics or other observed variability in effects that are not reducible by more 
information. 
Discussion 
22. Study findings, limitations, generalisability, 
and current knowledge 
Summarise key study findings and describe how they support the conclusions reached. 
Discuss limitations and the generalisability of the findings and how the findings fit with 
current knowledge. 
Other 
23. Source of funding 
Describe how the study was funded and the role of the funder in the identification, design, 
conduct, and reporting of the analysis. Describe other non-monetary sources of support. 
24. Conflicts of interest 
Describe any potential for conflict of interest of study contributors in accordance with 
journal policy. In the absence of a journal policy, we recommend authors comply with 
International Committee of Medical Journal Editors recommendations. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
 
 
23 
 
Appendix Table 2- Quality assessment 
Economic evaluation 
checklist/ Study name 
Field et al 
(1995) 
Langham 
et al (1996) 
Lindholm 
et al (1996) 
Wonderling 
et al (1996 
a) 
Wonderling 
et al (1996 
b) 
Finkelstein 
(2002) 
Yosefy et 
al (2003a) 
Yosefy et al 
(2003b) 
Finkelstein 
et al (2006) 
Yosefy et al 
(2007) 
Department 
of Health, 
UK (2008) 
Mistry et al 
(2012) 
Sovic et al 
(2013) 
Schuetz et 
al (2013) 
Aljutaili et 
al (2014) 
1 Title done done done done done done not done done done done done done done done done 
2 Study perspective not clear not clear done not clear not clear not clear not clear not clear not clear not clear done done done done not clear 
3 Time horizon done done done not clear done done not clear done done done done done done done done 
4 Discount rate done not clear done not clear not clear done done done done done done done done done done 
5 
Choice of health 
outcomes 
done done done done done done done done done done done done done done done 
6 
Measurement of 
effectiveness 
done done not clear done done done done done done done done done done done done 
7 
Estimating resources 
and costs 
done done done done done done not clear done done done  done done done done done 
8 
Currency, price data, 
and conversion 
done not clear done done not clear not clear not done done done done  done done done done done 
9 Choice of model done done done done done done not clear not clear done done  done done done done done 
10 Assumption not clear not clear done not clear done done not clear done done done done done done done done 
11 Analytical methods not clear not clear not clear not clear not clear not clear not done not done done not done done done done done done 
12 Study parameters not clear done not done done done done not done not done done not clear done done done done done 
13 
Incremental costs and 
outcomes  
done done not clear done done done not done not done done done  done done done done done 
14 
Characterising 
uncertainty 
not done not done not clear not clear not done not done not done not done done not clear done done done done done 
15 
Characterising 
heterogeneity 
done done not done done done not done not done not done not done not done done done done done done 
Overall Score 
moderate 
quality 
moderate 
quality 
moderate 
quality 
moderate 
quality 
moderate 
quality 
moderate 
quality 
low 
quality 
moderate 
quality 
high 
quality 
moderate 
quality 
high 
quality 
high 
quality 
high 
quality 
high 
quality 
high 
quality 
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Appendix Table 3- Characteristics of the CVD Risks Assessment and Management Programme 
  
Field et al 
(1995) 
Langham 
et al 
(1996) 
Lindholm 
et al 
(1996) 
Wonderling 
et al (1996 
a) 
Finkelstein 
(2002) 
Finkelstein 
et al 
(2006) 
Yosefy et 
al (2003a) 
Yosefy et 
al (2003b) 
Department 
of Health, 
UK (2008) 
Mistry et 
al (2012) 
Sovic et al 
(2013) 
Schuetz et 
al (2013) 
Aljutaili et 
al (2014) 
Risk Factors Screened                           
BMI v v   v v v v v v v v v   
Blood pressure v v v v v v v v v v v v   
Smoking  v v v v v v v v v v v v   
Alcohol  v v                       
Physical activity   v     v v     v v v v   
Family history of CVD v v   v v v   v v v v v   
Diet v v               v v     
Blood cholesterol  v v v v v v v v v v v v   
Blood glucose       v v v v   v v v v   
Not Sure                         v 
Additional Intervention                           
Follow up  v v v v v v v v v v v v v 
Advice on reducing risk 
factors 
v   v   v v v v v v v v v 
Drug prescription v       v v v v v v v v v 
Physical activity         v v v v v     v v 
Nutrition/Diet/Weight loss     v   v v v v v     v v 
Smoking cessation         v v v v v v v v v 
Health Care Provider                           
Nurse led v v   v         v v v v   
physician lead             v   v     v   
Nurse + Physician               v           
Not Sure     v   v v             v 
Location of Screening                           
General practice and hospital v v v v     v   v v v v   
Also in other community 
centres 
        v v   v           
Not Sure                         v 
Comparators                           
Usual care   v v v   v v v v v v v v 
Other alternatives v       v       v     v v 
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